Entero Therapeutics, Inc. announced a 1 for 3 reverse stock split of its common stock.
The reverse stock split aims to help the company regain compliance with Nasdaq listing requirements.
This strategic move will consolidate the outstanding common stock shares.
Reverse Stock Split
Every 3 shares will be consolidated into 1 share, reducing outstanding shares.
Compliance Strategy
The reverse split is part of a plan to meet Nasdaq's bid price requirement.
CEO's Statement
Interim CEO emphasizes the importance of Nasdaq listing for shareholder value.
- The reverse stock split may impact the trading dynamics of Entero Therapeutics, Inc.'s common stock.
- Shareholders will see a reduction in the total number of outstanding shares, potentially impacting stock liquidity.
Entero Therapeutics, Inc.'s reverse stock split reflects proactive measures to strengthen its position in the market. The company's focus on compliance and shareholder value demonstrates a strategic approach to corporate governance.